Editorial
The genetic heterogeneity of hepatocellular carcinoma and the implications for personalised medicine
Translational Cancer Research
2016;
5
(Suppl 1)
:S1-S4
.
(27 June 2016)
Allogeneic anti-CD19 CAR T cells: new perspectives in the treatment of B-cell malignancies that progress after allogeneic stem cell transplantation?
Translational Cancer Research
2016;
5
(Suppl 1)
:S5-S8
.
(27 June 2016)
Gene therapy-based prophylaxis to rescue the “prima ballerina”
Translational Cancer Research
2016;
5
(Suppl 1)
:S9-S12
.
(27 June 2016)
The role of nuclear factor-kappa B and endoplasmic reticulum stress in hepatitis B viral-induced hepatocellular carcinoma
Translational Cancer Research
2016;
5
(Suppl 1)
:S13-S17
.
(27 June 2016)
Dual targeting of EGFR: ready for prime time?
Translational Cancer Research
2016;
5
(Suppl 1)
:S18-S21
.
(27 June 2016)
Expanding treatment options for metastatic gastric cancer
Translational Cancer Research
2016;
5
(Suppl 1)
:S22-S24
.
(27 June 2016)
Moving molecular subtypes to the clinic in gastric cancer
Translational Cancer Research
2016;
5
(Suppl 1)
:S25-S30
.
(27 June 2016)
Clinical translation of predictive markers for anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer
Translational Cancer Research
2016;
5
(Suppl 1)
:S31-S34
.
(27 June 2016)
Taking action on actionable mutations: a French initiative on universality in precision cancer care
Translational Cancer Research
2016;
5
(Suppl 1)
:S35-S39
.
(27 June 2016)
Intraoperative subtyping of lung adenocarcinoma: an unmet need
Translational Cancer Research
2016;
5
(Suppl 1)
:S40-S43
.
(27 June 2016)
Is there really a role for the comprehensive geriatric assessment in metastatic non-small cell lung cancer?
Translational Cancer Research
2016;
5
(Suppl 1)
:S44-S46
.
(27 June 2016)
Screening for mutations in lung cancer in France: purpose of precision medicine
Translational Cancer Research
2016;
5
(Suppl 1)
:S47-S49
.
(27 June 2016)
Clinical significance of miR-15 and miR-16 in ovarian cancer
Translational Cancer Research
2016;
5
(Suppl 1)
:S50-S53
.
(27 June 2016)
Microtubule targeting agents in glioma
Translational Cancer Research
2016;
5
(Suppl 1)
:S54-S60
.
(27 June 2016)
Gated chimeric antigen receptor T-cells: the next logical step in reducing toxicity?
Translational Cancer Research
2016;
5
(Suppl 1)
:S61-S65
.
(27 June 2016)
Innate immunosurveillance: the next frontier in the cancer immunotherapy toolbox
Translational Cancer Research
2016;
5
(Suppl 1)
:S66-S70
.
(27 June 2016)
Perspective
Surrounding break up after Helicobacter pylori eradication to prevent metachronous gastric cancer after endoscopic submucosal resection
Translational Cancer Research
2016;
5
(Suppl 1)
:S71-S75
.
(27 June 2016)
Precision oncology: identifying predictive biomarkers for the treatment of metastatic renal cell carcinoma
Translational Cancer Research
2016;
5
(Suppl 1)
:S76-S80
.
(27 June 2016)
Commentary
Identification of molecular subtypes and significantly mutated genes in gastric cancer using next-generation sequencing
Translational Cancer Research
2016;
5
(Suppl 1)
:S81-S83
.
(27 June 2016)
Biomarkers and stage II colorectal cancer therapy
Translational Cancer Research
2016;
5
(Suppl 1)
:S84-S86
.
(27 June 2016)
The role of Sym004, a novel EGFR antibody mixture, in patients with refractory colorectal cancer
Translational Cancer Research
2016;
5
(Suppl 1)
:S87-S90
.
(27 June 2016)
Unearthing a novel tumor suppressor function of ATOH8 in hepatocellular carcinoma: role in acquisition of cancer stem cell-like features
Translational Cancer Research
2016;
5
(Suppl 1)
:S91-S94
.
(27 June 2016)
Impact of genomic heterogeneity associated with acquired anti-EGFR resistance in colorectal cancers
Translational Cancer Research
2016;
5
(Suppl 1)
:S95-S98
.
(27 June 2016)
Can we effective use sym004 in tumours harboring EGFR extracellular domain mutations?
Translational Cancer Research
2016;
5
(Suppl 1)
:S99-S100
.
(27 June 2016)
MET exon 14 mutation: another actionable genomic variation in patients with advanced NSCLC
Translational Cancer Research
2016;
5
(Suppl 1)
:S101-S105
.
(27 June 2016)
Repurposing an HIV drug to improve efficacy of targeted therapy in melanoma
Translational Cancer Research
2016;
5
(Suppl 1)
:S106-S108
.
(27 June 2016)
Commentary on the GEC-ESTRO trial: is partial breast irradiation ready for prime time?
Translational Cancer Research
2016;
5
(Suppl 1)
:S109-S112
.
(27 June 2016)
Adjuvant endocrine therapy for post-menopausal women with ductal carcinoma in situ—is the pain worth the gain?—a commentary on the NSABP-B35 trial
Translational Cancer Research
2016;
5
(Suppl 1)
:S113-S116
.
(27 June 2016)
Concurrent or sequential letrozole with adjuvant breast radiotherapy
Translational Cancer Research
2016;
5
(Suppl 1)
:S117-S119
.
(27 June 2016)
Concurrent or sequential letrozole with adjuvant breast radiotherapy
Translational Cancer Research
2016;
5
(Suppl 1)
:S120-S122
.
(27 June 2016)
Fat lure: adipocytes attract cancer cells out of the prostate
Translational Cancer Research
2016;
5
(Suppl 1)
:S123-S125
.
(27 June 2016)
Surgical intervention and circulating tumor cell count: a commentary
Translational Cancer Research
2016;
5
(Suppl 1)
:S126-S128
.
(27 June 2016)
Fat talks: a new role for adipose tissue in promoting prostate cancer in obesity
Translational Cancer Research
2016;
5
(Suppl 1)
:S129-S132
.
(27 June 2016)
miR-15a and miR-16 supplementation as a potential remedy for ovarian cancer
Translational Cancer Research
2016;
5
(Suppl 1)
:S133-S135
.
(27 June 2016)
Emerging roles in prolactin-mediated BRCA1 function
Translational Cancer Research
2016;
5
(Suppl 1)
:S136-S138
.
(27 June 2016)
Epigenetics of cancer: the role of histone methyltransferase, SETDB1, in cancer metastasis
Translational Cancer Research
2016;
5
(Suppl 1)
:S139-S141
.
(27 June 2016)
A novel role for Cish in the inhibition of TCR signaling
Translational Cancer Research
2016;
5
(Suppl 1)
:S142-S145
.
(27 June 2016)
Role of c-MYC/miRNA-548/HDAC6 axis in drug resistance and lymphoma survival
Translational Cancer Research
2016;
5
(Suppl 1)
:S146-S148
.
(27 June 2016)
Correspondence
Radiation, cytokines and T-cell checkpoints: can we cure metastatic cancer?
Translational Cancer Research
2016;
5
(Suppl 1)
:S149-S150
.
(27 June 2016)
News
2015 impact factor of Translational Cancer Research: 1.757
Translational Cancer Research
2016;
5
(Suppl 1)
:S151
.
(27 June 2016)
Disclosure:
This supplement was published without any sponsorship or funding.